PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

72 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
21.
Jensen, P.* et al.: Requirement for LIM kinases in acute myeloid leukemia. Leukemia 34, 3173–3185 (2020)
22.
Mason, M.J.* et al.: Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia 34, 1866–1874 (2020)
23.
Ruzicka, M.* et al.: RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. Leukemia 34, 1017-1026 (2020)
24.
Stegelmann, F.* et al.: Significant association of cutaneous adverse events with hydroxyurea: Results from a prospective non-interventional study inBCR-ABL1-negative myeloproliferative neoplasms (MPN)-on behalf of the German Study Group-MPN. Leukemia, DOI: 10.1038/s41375-020-0945-3 (2020)
25.
Stief, S.M.* et al.: Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia 34, 50-62 (2020)
26.
Tirado-Gonzalez, I.* et al.: Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC (Leukemia, (2018), 32, 4, (1048-1051), 10.1038/leu.2017.346). Leukemia 35:294 (2020)
27.
Angenendt, L.* et al.: The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia 33, 2830-2841 (2019)
28.
Lynch, J.R.* et al.: JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. Leukemia 33, 1400-1410 (2019)
29.
Vrzalikova, K.* et al.: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells (vol 32, pg 214, 2018). Leukemia 33, 2126-2126 (2019)
30.
Anastasiadou, E.* et al.: Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 33, 132–147 (2018)
31.
Reiter, K.* et al.: Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia 32, 313-322 (2018)
32.
Schneidt, V.* et al.: Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo. Leukemia 33, 88-98 (2018)
33.
Tirado-Gonzalez, I.* et al.: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia 32, 1048-1051 (2018)
34.
Neuenhahn, M. et al.: Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia 31, 2161-2171 (2017)
35.
Vrzalikova, K.* et al.: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells. Leukemia 32, 214-223 (2017)
36.
Wurster, K.D.* et al.: Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma. Leukemia 31, 602-613 (2017)
37.
Dutta, S. et al.: The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models. Leukemia 30, 1166-1176 (2016)
38.
Krupka, C. et al.: Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3-BiTE antibody construct AMG 330: Reversing a T-cell induced immune escape mechanism. Leukemia 30, 484-491 (2016)
39.
Spinner, S.* et al.: Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. Leukemia 30, 1520-1530 (2016)
40.
Alsadeq, A.* et al.: Effects of p38α/β inhibition on Acute Lymphoblastic Leukemia (ALL) proliferation and survival in vivo. Leukemia 29, 2307-2316 (2015)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮